Kerrie Davies is an NIHR Clinical Lecturer, Principal Clinical Scientist, she was the Deputy Lead for Infection on the NIHR Leeds MedTech Invitro Diagnostics Cooperative (MIC), and is currently Co-lead for the Early Diagnosis and Personalised Care theme of the HealthTech Research Centre, and Deputy theme lead within the Infection and AMR theme of the NIHR Leeds Biomedical Research Centre (BRC), within the Healthcare Infections Research Group at Leeds Teaching Hospitals NHS Trust; Honorary Associate Professor of diagnostic for infectious disease at University of Leeds; Senior Scientific Advisor to the Office of the Chief Scientific Officer at NHS England; Co-chair Empower Leeds Women, and Education lead for the European Society of Clinical Microbiology and Infectious Disease study group committee for C. difficile. During the pandemic she was seconded first into DHSC, and then UKHSA, to lead on validating COVID-19 diagnostic assays, then contributing to writing and setting up, then operationalising new regulatory legislation (Coronavirus Test Device Approval 2021) for COVID-19 test devices.
Kerrie has been researching in vitro diagnostics for >20 years, both nationally and internationally, including defining the optimal C. difficile testing algorithm which was adopted in the UK and recommended in European, American, and Australasian testing guidelines. She has a passion for the impact of research on patients and healthcare, and in particular supporting Healthcare Scientists in research careers and was awarded CSO Healthcare Scientist of the year in 2021 for her work on COVID-19 diagnostics.